Abstract # P-15: Incremental Burden of Type 2 Diabetes Mellitus in Patients Hospitalized for Heart Failure

2016 ◽  
Vol 22 ◽  
pp. 20-21
Author(s):  
Aditya D. Raju ◽  
Anna D. Coutinho ◽  
Weijia Wang ◽  
Sharash Shetty ◽  
Stephen S. Sander ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus

1142-P: Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1142-P
Author(s):  
DOMINIC PILON ◽  
MICHAEL DURKIN ◽  
AMEUR MANCEUR ◽  
ISABELLE GHELERTER ◽  
MARIE-HÉL LAFEUILLE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus

Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction

2019 ◽  
Vol 19 (20) ◽  
pp. 1818-1849 ◽  
Author(s):  
Ban Liu ◽  
Yuliang Wang ◽  
Yangyang Zhang ◽  
Biao Yan
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Dysfunction ◽  
Sglt2 Inhibitors ◽  
Sodium Glucose Cotransporter ◽  
Glucose Reabsorption ◽  
Renal Glucose Reabsorption

: Type 2 diabetes mellitus is one of the most common forms of the disease worldwide. Hyperglycemia and insulin resistance play key roles in type 2 diabetes mellitus. Renal glucose reabsorption is an essential feature in glycaemic control. Kidneys filter 160 g of glucose daily in healthy subjects under euglycaemic conditions. The expanding epidemic of diabetes leads to a prevalence of diabetes-related cardiovascular disorders, in particular, heart failure and renal dysfunction. Cellular glucose uptake is a fundamental process for homeostasis, growth, and metabolism. In humans, three families of glucose transporters have been identified, including the glucose facilitators GLUTs, the sodium-glucose cotransporter SGLTs, and the recently identified SWEETs. Structures of the major isoforms of all three families were studied. Sodium-glucose cotransporter (SGLT2) provides most of the capacity for renal glucose reabsorption in the early proximal tubule. A number of cardiovascular outcome trials in patients with type 2 diabetes have been studied with SGLT2 inhibitors reducing cardiovascular morbidity and mortality. : The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed down the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.

GDF-15 and neutrophils in patients with heart failure and type 2 diabetes mellitus

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
AA Garganeeva ◽  
EA Kuzheleva ◽  
VA Fedyunina ◽  
VA Aleksandrenko
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Inflammatory Marker ◽  
Study Groups ◽  
Significant Negative Correlation ◽  
Enzyme Linked Immunosorbent Assay ◽  
National Budget

Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This study was funded by (subject of fundamental scientific research on a state assignment № АААА-А17-117052310073-6 от 23.05.2017 Introduction. Growth differentiation factor-15 (GDF-15) is a biomarker associated with inflammatory processes in the pathogenesis of chronic heart failure (CHF) which expresses in cardiomyocytes under pathological conditions. The relationship between the level of GDF-15 and type 2 diabetes mellitus (T2DM) has also been proven. It is necessary to study GDF-15 in patients with CHF and T2DM. Aim To investigate the association between serum GDF-15 levels in patients with CHF of ischemic etiology and the concentration of the main leukocyte fractions depending on presence or absence of T2DM. Material and methods. The study included 42 patients. The patients were divided into 2 groups. The first group consisted of patients with CHF and T2DM (n = 14). The second group  consisted of patients with CHF without T2DM (n = 28). Determination of GDF-15 concentration was carried out by enzyme-linked immunosorbent assay (BioVendor, Czech Republic). The absolute concentration of lymphocytes, neutrophils, as well as the ratio of neutrophils to lymphocytes in the blood were analyzed. Statistical analysis was performed using the Statistica software (v.10.0). The data were described as a median and interquartile range, the Mann-Whitney test was used to compare them. The correlation analysis was tested using the Spearman"s correlation coefficient. Results and discussion. The average level of the GDF-15 in the study groups was comparable: 2389 (2104; 3375) pg/ml and 2309 (2047; 3014) pg/ml in the first and second groups, respectively (p = 0.6). In the general cohort of CHF patients, the GDF-15 concentration was not correlate with the lymphocytes concentration (r = -0.001, p = 0.95), neutrophils (r = -0.14, p = 0.4) and the ratio of neutrophils to lymphocytes (r = -0.12, p = 0.25). At the same time, in the group of patients with T2DM, a significant negative correlation was revealed between the concentration of GDF-15 in the serum and the concentration of neutrophils (r = -0.6, p = 0.022). While both other analyzed parameters did not demonstrate significant correlations with GDF-15 (p > 0.05). In the group of CHF patients without T2DM, no correlations were found between GDF-15 and the studied parameters, including neutrophils (r = 0.02, p = 0.3). Along with this the median of the neutrophils concentration did not vary among groups (3.5 (2.3; 5.3) vs 3.2 (2.7; 4.1) * 109 / l; p = 0.8). Conclusion The concentration of the inflammatory marker GDF-15 in the blood of patients with CHF in combination with T2DM correlates with the concentration of neutrophils. In the absence of T2DM, no significant correlations were found between GDF-15 and the main leukocyte fractions. The results obtained indicate the possible prospect of using the GDF-15 biomarker in a cohort of patients with CHF in combination with T2DM.

scholarly journals Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years

2021 ◽  
Vol 32 ◽  
pp. 100739
Author(s):  
Claire A Lawson ◽  
Samuel Seidu ◽  
Francesco Zaccardi ◽  
Gerry McCann ◽  
Umesh T Kadam ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Failure Type ◽  
The Uk

scholarly journals CARDIOPULMONARY EXERCISE TEST IN TYPE 2 DIABETES MELLITUS IN ABSENCE OF CHRONIC HEART FAILURE: REDUCED LUNG AND HEART FUNCTION

2018 ◽  
Vol 26 (2) ◽  
pp. 34
Author(s):  
Danilo Rodrigues Bertucci ◽  
Nuno Manuel Frade De Sousa ◽  
Gabriella Souza Soares ◽  
Danielle Pinheiro Albano ◽  
Giovanna Benjamin Togashi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Heart Function ◽  
Cardiopulmonary Exercise Test ◽  
Cardiopulmonary Exercise ◽  
Circulatory Power ◽  
Oxygen Uptake Efficiency Slope

Comparar a tolerância ao exercício, funções respiratória e cardiovascular entre indivíduos não diabéticos e diabéticos tipo 2 sem doenças crônicas cardíacas. Treze homens normoglicêmicos (NDG) e oito homens diabéticos tipo 2 (DG) que realizaram um teste cardiopulmonar de esforço (TCPE) em uma esteira motorizada (o teste iniciou-se em 3km.h-1 com incremento de 1km.h-1 a cada dois minutos) que avaliou a função respiratória, parâmetros cardiovasculares e tolerância ao exercício. Valores de consumo de oxigênio e intensidades na intensidade do limiar ventilatório foram significativamente menores para o DG (DG: 5,6 ± 0,5 km/h-1 e 13,1 ± 3,8 ml.(kg.min)-1; NDG: 6,5 ± 0,5 km/h-1 e 16,4 ± 2,8 ml.(kg.min)-1; p < 0,05). Consumo de oxigênio pico e intensidade associada foram significativamente menores para o DG (DG: 22,7 ± 5,7 ml.(kg.min)-1; 8,2 km/h-1 ± 0,7 km/h-1) quando comparado com o NDG (30,8 ± 5,4 ml.(kg.min)-1; 11,6 ± 1,5 km/h). Oxygen uptake efficiency slope (OUES) e circulatory power foram significativamente menores para o DG (p < 0,05) embora não foram encontradas diferenças significativas na eficiência ventilatória. Em indivíduos portadores de diabetes tipo 2, mesmo sem a presença conhecida de doenças cardiovasculares, apresentaram menores níveis de condicionamento cardiorrespiratório e tolerância ao exercício. Circulatory power pico e OUES também foram reduzidos nesses indivíduos.

Sign in / Sign up

Export Citation Format

Share Document